KRAS-mutated colorectal cancer: what the exact result changes

Read the letters after KRAS

A report may identify G12C, G12D, G12V or another alteration. These are different variants of the same gene, and a medicine aimed at one cannot simply be substituted for another. Ask for the complete laboratory report, including the sample date and whether it came from tissue or blood.

The most immediate relevance is usually in advanced colorectal cancer. For a patient with a localized tumor that can be removed, stage and surgical pathology remain central. Do not assume a molecular result overrides a potentially curative surgical plan.

Sources and references: [1]

Why the result affects anti-EGFR drugs

KRAS is part of a cell-growth signaling pathway. An activating KRAS alteration can keep signaling active downstream of EGFR. This helps explain why standard cetuximab or panitumumab strategies used for suitable RAS-wild-type cancers generally do not apply to KRAS-mutated tumors.

There is an important specific exception: an EGFR antibody can form part of a combination with a KRAS G12C inhibitor. That combination addresses the signaling pathway differently. If two recommendations seem contradictory, check whether one is discussing conventional anti-EGFR treatment and the other a G12C-targeted combination.

Sources and references: [1] [2] [3]

What is established for KRAS G12C?

In the United States, adagrasib plus cetuximab received accelerated approval in 2024 for defined previously treated KRAS G12C-mutated advanced colorectal cancer. Sotorasib plus panitumumab received approval in 2025 for KRAS G12C-mutated metastatic disease after prior fluoropyrimidine, oxaliplatin and irinotecan treatment.

These indications are specific to the combination, mutation and treatment history. A lung cancer prescription for the same inhibitor is not a ready-made colorectal cancer plan. When considering treatment in China, ask the specialist to identify the applicable local indication and the practical access route.

Sources and references: [2] [3]

What if the mutation is not G12C?

Chemotherapy and other appropriate systemic treatments remain important. A team may use an anti-VEGF approach or consider a study matched to the exact KRAS variant, depending on stage and prior therapy. The label KRAS-mutated should not close the discussion before those options are reviewed.

New KRAS-directed medicines and combinations are being studied, but the eligibility details matter. Ask whether a proposed option is approved for this cancer and variant or is being offered through a clinical trial. For a study, request its identifier and current site-level screening requirements.

Sources and references: [1] [4]

Keep the rest of the molecular profile in view

MSI-H or dMMR can create an immunotherapy option even when a KRAS mutation is present. Additional test results may also affect later choices. A useful molecular review organizes findings by what they change now, what may matter later and what has no established treatment implication.

Testing can also raise inherited-risk questions, but a tumor KRAS mutation by itself is not a diagnosis of an inherited cancer syndrome. Ask separately whether the personal or family history calls for genetic counseling or germline testing.

Sources and references: [1] [5]

Compare treatment burden as well as the target

Targeted treatment still needs monitoring. G12C combinations can cause gastrointestinal symptoms, rash, fatigue and liver-test abnormalities, among other effects. The EGFR antibody requires its own infusion and skin-care plan. Bring all prescription medicines and supplements for interaction review.

Ask how often blood tests and clinic visits are needed, how missed doses are handled and which symptoms should prompt a call. If neuropathy or poor appetite already limits daily life, make that explicit. The practical fit of a regimen can be as important as its molecular rationale.

Sources and references: [2] [1]

When a working treatment stops working

The team first confirms progression and checks whether it is widespread or limited to a small number of sites. Previous benefit, remaining options and current health determine the next step. Repeating a molecular test may be useful if it could identify a resistance mechanism or trial eligibility.

A new blood test is not automatically the answer to every progression. Ask what decision the result would change, whether tissue is also needed and how long it will take. Keep symptom treatment moving while those questions are resolved.

Sources and references: [1] [5]

Preparing a molecular treatment review in Shanghai

A consultation with a colorectal oncology team should receive the full sequencing report and every previous regimen. Our Fudan Cancer Center profile is one starting point for a Shanghai inquiry.

EastMedGo can help turn the records into a focused question, such as whether a G12C combination fits after prior chemotherapy. Use contact to share the report and current plan. We can coordinate communication about specialist assessment, laboratory material requirements and expected visit arrangements.

Sources and references: [6]

Common questions